Healthcare, Pharma & Life Sciences

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX) plans to run the first part of its two-part XRX-OXY-102 gout study in Canada, a move it expects to speed delivery of the clinical data needed for a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).

XORTX prepares Health Canada filing in parallel with FDA track

The company has outlined an anticipated Clinical Trial Application (CTA) to Health Canada for its XRx-026 gout program. The study evaluates XORLO, XORTX's proprietary formulation of oxypurinol, a xanthine oxidase inhibitor. Drug development teams have been preparing the CTA in parallel with the planned FDA NDA submission.

Tampa – October 12, 2026 -- Blue Purpose founder Don Glidewell has been awarded his third U.S. patent tied to BOOMBOX, his emergency communications technology, extending an intellectual property portfolio built over more than 20 years in long-term care technology.

BOOMBOX addresses a specific operational problem: enabling organizations to communicate when emergencies disrupt normal operations. The latest patent expands Glidewell's holdings in emergency communications for mission-critical environments. The source does not disclose the patent's number, filing date or claims.

Jersey City – October 12, 2026 -- Subcutaneous (SC) infliximab delivered clinical remission in 71.4% of matched patients with ileum-dominant Crohn's disease at Week 54, against 51.4% for intravenous (IV) infliximab, according to a late-breaking analysis Celltrion USA will present for ZYMFENTRA (infliximab-dyyb) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.

Matched analysis shows wider endoscopic gap for SC infliximab at Week 54

The pooled analysis used individual patient data from four infliximab registrational studies. Of 884 patients, 200 with ileal or ileocolonic Crohn's disease met eligibility criteria. They received either SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. A 1:1 propensity score-matched analysis included 70 patients per arm.

SC infliximab outperformed IV infliximab on all three measures in the matched population:

Braintree, Mass. – October 12, 2026 -- Braintree Laboratories, part of Sebela Pharmaceuticals, reported that its investigational P-CAB tegoprazan delivered statistically significant gains over placebo in both heartburn and regurgitation in the 783-patient Phase 3 TRIUMpH-NERD study. The company describes it as the first P-CAB to show clinical improvement in both hallmark non-erosive reflux disease (NERD) symptoms in a prospective U.S. Phase 3 trial.

Both tegoprazan doses meet primary and key secondary endpoints

TRIUMpH-NERD (NCT05587322) was a randomized, double-blind, placebo-controlled, multicenter study. Patients received tegoprazan 50 mg, tegoprazan 100 mg or placebo once daily for four weeks, followed by a 20-week extension. The primary endpoint was the percentage of 24-hour heartburn-free days through Week 4. Days without nighttime heartburn was a key secondary endpoint, and regurgitation was a prespecified exploratory endpoint.

Plano, Texas – October 11, 2026 -- AnX Robotica said its NaviCam ProScan AI reading technology cut mean small-bowel capsule endoscopy review time by 88.6% in the study underlying its FDA De Novo clearance, against a 24.7% reduction reported for a competing AI-assisted platform cleared on September 25, 2026.

FDA names ProScan as primary predicate for the new clearance

The FDA's 510(k) clearance K254230 identifies NaviCam ProScan (DEN230027) as its primary predicate device. Both products assist clinicians reviewing small-bowel capsule endoscopy studies. ProScan received its De Novo decision on December 12, 2023.

New Delhi – October 10, 2026 -- The India Mental Health Alliance (IMHA), a network of 400 organisations across 30 Indian states, is building a shared Knowledge Hub and has published a 11-author anthology to make lived experience a formal input into mental healthcare design and delivery.

IMHA reached 3,380 professionals in 135+ cities over two years

Over the past two years, the alliance engaged 3,380 mental health professionals across more than 135 cities. It mobilised member organisations to build collective capacity, share knowledge and embed lived experience expertise in care design and practice.

The announcement coincides with World Mental Health Day on October 10.

Knowledge Hub will pool clinical, lived and academic evidence

IMHA is developing a co-curated Knowledge Hub that collects practitioner insights, field lessons, clinical and lived experience expertise, and academic research grounded in local Indian contexts.

Milan – October 10, 2026 -- WuXi Biologics is pitching a European manufacturing footprint of 54,000 L of drug-substance capacity in Dundalk, Ireland, plus a 12,000 L site in Wuppertal, Germany, to biopharma clients at CPHI Milan 2026, as Europe's biologics market is projected to grow from an estimated US$123.75 billion in 2025 to about US$269.65 billion by 2035.

The market is forecast to expand at a CAGR of 8.1% from 2026 to 2035. CPHI Milan 2026 brings together more than 62,000 pharmaceutical professionals and 2,900 exhibitors.

Dundalk hub runs 54,000 L across perfusion and fed-batch platforms

The Dundalk site operates under an HPRA GMP manufacturing license, supports EMA-approved commercial products and has served more than 10 clients. In 2026, it secured multiple new large-scale manufacturing projects and began the associated technology transfers.

Bloomfield – – October 09, 2026 -- The Cigna Group (NYSE:CI) will release its third quarter 2026 financial results no later than 6:30 a.m. ET on Thursday, November 5, 2026, giving investors two hours before management takes questions on a conference call.

Cigna schedules management call for 8:30 a.m. ET on results day

Management will review the quarter's results on a conference call starting at 8:30 a.m. ET on November 5. The company recommends that participants dial in by 8:15 a.m. ET.

Cigna sets 14-day replay window through November 19

A replay will be available from 12:30 p.m. ET on November 5 until 10:59 p.m. ET on November 19, 2026. A live internet webcast, in listen-only mode, will run through the Investor Relations section of the company's website.

The earnings news release and financial supplement will be posted in the same Investor Relations section no later than 6:30 a.m. ET on the day of the release.

Genoa – – October 09, 2026 -- Midea Group has completed the acquisition of a controlling stake in Esaote S.p.A., the Italian medical imaging maker that posted fiscal 2025 revenues of EUR 267 million, 70% of them from international markets.

Esaote joins Midea Healthcare as an independent company

Esaote becomes part of Midea's Healthcare Division but will continue to operate as an independent global medical equipment company. It stays headquartered in Genoa, with R&D and manufacturing facilities in Italy and the Netherlands. Franco Fontana remains CEO, confirmed by the new shareholders.

Midea's DR, MRI, CT and DSA lines meet Esaote's ultrasound and open MRI strengths

Midea's portfolio covers DR, high-field MRI, CT and DSA. Esaote contributes premium-brand strengths in ultrasound, open and dedicated MRI systems and medical IT solutions. Esaote ranks among the top ten global manufacturers of ultrasound and of open and dedicated MRI.

Piscataway, N.J. – October 08, 2026 -- GenScript Biotech Corporation and NVIDIA have launched a global startup competition pairing wet lab validation with accelerated computing to push AI-driven drug discovery toward commercial proof points.

Up to six finalists will pitch before judges during JPM Week in January

The GenScript and NVIDIA Life Sciences Startup PitchFest opened applications today, with finalists confirmed in December. Up to six companies will be selected for a GenScript-hosted pitch event during JPM Week, competing before a panel of judges for a winning slot.